SCHEMBL20508356

SCHEMBL20508356

O=C(CCCc1ccc(-c2cccnc2)cc1)Nc1ccc(O)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 4/20 0.67
MEN1 O00255 1/20 0.60
ALDH1A1 P00352 1/20 0.60
CYP3A4 P08684 1/20 0.60
MAPT P10636 1/20 0.60
TSHR P16473 1/20 0.60
MAPKAPK2 P49137 1/20 0.60
KMT2A Q03164 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
CHRNA7 P36544 1/20 0.58
WNT3A P56704 1/20 0.58
MAP4K4 O95819 1/20 0.53
ABL1 P00519 1/20 0.53
NTRK1 P04629 1/20 0.53
LCK P06239 1/20 0.53
FYN P06241 1/20 0.53
CSF1R P07333 1/20 0.53
RET P07949 1/20 0.53
IGF1R P08069 1/20 0.53
PDGFRB P09619 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21045563 0.89 HDAC3 (0.60) TRPV1MEN1KMT2ACHRNA7WNT3A
SCHEMBL29411532 0.89 HDAC3 (0.60) TRPV1MEN1KMT2ACHRNA7WNT3A
SCHEMBL17986846 0.87 TRPV1 (0.51) TRPV1MEN1ALDH1A1CYP3A4MAPT
SCHEMBL20508332 0.86 TRPV1 (0.63) TRPV1MEN1ALDH1A1CYP3A4MAPT
SCHEMBL21045372 0.84 LMNA (0.64) TRPV1MEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL29411445 0.82 HDAC3 (0.57) TRPV1MEN1KMT2ASMN1; SMN2
SCHEMBL21045351 0.82 HDAC3 (0.57) TRPV1MEN1KMT2ASMN1; SMN2
SCHEMBL21045456 0.81 HDAC3 (0.60) TRPV1MEN1KMT2ASMN1; SMN2
SCHEMBL29411426 0.81 HDAC3 (0.60) TRPV1MEN1KMT2ASMN1; SMN2
SCHEMBL31315988 0.81 ALDH1A1 (0.63) TRPV1MEN1ALDH1A1CYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119192065-A Anticancer compounds 悉尼大学 2024-12-27 CN disclosed
EP-3250551-B1 ANTI-CANCER COMPOUNDS UNIV SYDNEY (AU) 2022-11-09 EP disclosed
US-10745355-B2 Anti-cancer compounds THE UNIVERSITY OF SYDNEY (AU) 2020-08-18 US disclosed
US-10745355-B2 Anti-cancer compounds THE UNIVERSITY OF SYDNEY (AU) 2020-08-18 US disclosed
US-20180273478-A1 ANTI-CANCER COMPOUNDS THE UNIVERSITY OF SYDNEY (AU) 2018-09-27 US disclosed
CN-107207437-A Anticancer compounds 悉尼大学 2017-09-26 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180273478-A1 ANTI-CANCER COMPOUNDS MKI67, TP53, CDK5 TRPV1 4309/4885MEN1 467/4885ALDH1A1 1509/4885
US-10745355-B2 Anti-cancer compounds MKI67, TP53, CDK5 TRPV1 4309/4885MEN1 467/4885ALDH1A1 1509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.